248 related articles for article (PubMed ID: 11757204)
21. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Sakurai T
Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
[TBL] [Abstract][Full Text] [Related]
22. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
23. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Maxwell C; Swift R; Goode M; Doane L; Rogers M
Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid.
Cheer SM; Noble S
Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
[TBL] [Abstract][Full Text] [Related]
25. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR
J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945
[TBL] [Abstract][Full Text] [Related]
26. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
[TBL] [Abstract][Full Text] [Related]
27. Hypercalcemia of malignancy.
Body JJ
Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
[TBL] [Abstract][Full Text] [Related]
28. Bone disease in myeloma.
Berenson JR
Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
31. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Berenson JR
Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.
Massaro AM
Cancer Pract; 2002; 10(4):219-21. PubMed ID: 12100107
[No Abstract] [Full Text] [Related]
33. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
[TBL] [Abstract][Full Text] [Related]
34. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Pozzi S; Raje N
Oncologist; 2011; 16(5):651-62. PubMed ID: 21493759
[TBL] [Abstract][Full Text] [Related]
35. [Bisphosphonates and bone metastases].
Lortholary A; Jadaud E; Berthaud P
Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates in the treatment of skeletal metastases.
Conte P; Coleman R
Semin Oncol; 2004 Oct; 31(5 Suppl 10):59-63. PubMed ID: 15490377
[TBL] [Abstract][Full Text] [Related]
37. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
Ashcroft AJ; Davies FE; Morgan GJ
Lancet Oncol; 2003 May; 4(5):284-92. PubMed ID: 12732166
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
39. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
[TBL] [Abstract][Full Text] [Related]
40. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]